Background: Drug particle size determines the lung deposition of aerosolised medicine in
asthma,[1] but is unknown in COPD. Aerosol deposition and its lung distribution have …

Medical aerosols are key elements of current chronic obstructive pulmonary disease
(COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of …

Background: Drug particle size influences lung deposition and systemic bioavailability of
inhaled aerosols. We investigated the fate of 3 different particle sizes of inhaled fluticasone …

Background: Understanding the regional partition of deposition of inhaled particles within
the lung is important for improving targeted delivery of inhaled aerosolized drugs. One factor …

Introduction Inhaled drugs are the most commonly used class of medications for COPD
subjects. No studies have been performed to assess the influence of smoking on lung …

Introduction: Inhalation therapy is a cornerstone of treatment in COPD. The different
operation mechanisms of these devices influence drug delivery and pulmonary drug …

The in vitro assessment of the aerosol fine particle'respirable'fraction and the aerodynamic
particle size distribution on cascade impactors is necessary to meet the demands of …

The success of inhalation therapy is not only dependent upon the pharmacology of the
drugs being inhaled but also upon the site and extent of deposition in the respiratory tract …

Methods: AST (FEV1= 81% pred) & HS (FEV1= 100% pred) each inhaled 4 treatments in a
randomised crossover study. These were FP-50µg monodisperse particle sizes 1.5, 3, 6-µm …

INTRODUCTION Inhaled drugs can only be effective if they reach the middle and small
airways. This study introduces a system that combines a trans-nasal application of aerosols …